Search Free Newsletters

Pharma

Transforming health through business and innovation.

Novo Nordisk's CEO is out after the Ozempic maker's stock dropped 50% in a year

ByCatherine Baab

Trump's push for lower drug prices is just asking Big Pharma to make less money

Eli Lilly stock sinks as pharma misses out on the market rally

Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study

6 fast food chains rolling out frozen drinks for summer

ByKevin Williams

Weight Watchers goes bankrupt even as it tries to ride the Ozempic boom

Trump says pharmaceutical tariffs are coming. Here's what to expect

ByShannon Carroll

Weight loss drugs can help employers cut health care costs, study says

ByCatherine Arnst

Hims & Hers strikes a deal with Novo Nordisk to sell Wegovy — and the stock soars 28%

Copycat Ozempic makers just lost a big court fight

ByCatherine Arnst

Eli Lilly is stepping up its fight against copycat weight loss drugs

ByCatherine Arnst

Roche says it will invest $50 billion in the U.S. as tariff fears hit pharma

ByCatherine Arnst

Eli Lilly promises to make new weight loss pill in the U.S.

ByShannon Carroll

Eli Lilly's weight loss pill could be just as good as Ozempic — and the stock soars

ByShannon Carroll

Pfizer just had a big setback in its race for an Ozempic competitor

Hims & Hers stock slipped as investors were left unimpressed with its new weight-loss drug options

Novo Holdings' earnings nearly doubled in 2024, despite Novo Nordisk's stock slump

Here's how much Ozempic and similar drugs have soared in popularity since 2018

Eli Lilly is coming after makers of copycat versions of Zepbound

Eli Lilly and Novo Nordisk are tackling heart health next